Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Neumann

Showing results (11-20 of 301) with videos related to

Pageof 31
Sort By:
Mabs|January 5, 2010
Are mAbs different?: a comment on Cohen and WilsonPeter J Neumann
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 25, 2007
Budget impact analyses get some respectPeter J Neumann
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 17, 2013
Where are we on "risk-sharing" agreements?Peter J Neumann
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 13, 2019
Yes, Improve the US Value Frameworks, But Recognize They Are Already in Prime TimePeter J Neumann
Health Affairs (Project Hope)|January 30, 2007
Challenges ahead for federal technology assessmentPeter J Neumann
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 29, 2008
What ever happened to FDAMA Section 114? A look back after 10 yearsPeter J Neumann
Medical Care|August 2, 2005
The arrival of economic evidence in managed care formulary decisions: the unsolicited request processPeter J Neumann
Expert Review of Pharmacoeconomics & Outcomes Research|March 1, 2011
Does adjusting for health-related quality of life matter in economic evaluations of cancer-related interventions?Dan Greenberg, Peter J Neumann
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 25, 2022
Health technology assessment for gene therapies in haemophiliaJamie O'Hara, Peter J Neumann,
Value in Health Regional Issues|November 25, 2016
Cost-Effectiveness Analysis Expands its Reach WorldwideDan Greenberg, Peter J Neumann
Pageof 31

Showing results (11-20 of 301) with videos related to

Sort By:
Pageof 31
Mabs|January 5, 2010
Are mAbs different?: a comment on Cohen and WilsonPeter J Neumann
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 25, 2007
Budget impact analyses get some respectPeter J Neumann
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 17, 2013
Where are we on "risk-sharing" agreements?Peter J Neumann
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 13, 2019
Yes, Improve the US Value Frameworks, But Recognize They Are Already in Prime TimePeter J Neumann
Health Affairs (Project Hope)|January 30, 2007
Challenges ahead for federal technology assessmentPeter J Neumann
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|July 29, 2008
What ever happened to FDAMA Section 114? A look back after 10 yearsPeter J Neumann
Medical Care|August 2, 2005
The arrival of economic evidence in managed care formulary decisions: the unsolicited request processPeter J Neumann
Expert Review of Pharmacoeconomics & Outcomes Research|March 1, 2011
Does adjusting for health-related quality of life matter in economic evaluations of cancer-related interventions?Dan Greenberg, Peter J Neumann
Haemophilia : the Official Journal of the World Federation of Hemophilia|January 25, 2022
Health technology assessment for gene therapies in haemophiliaJamie O'Hara, Peter J Neumann,
Value in Health Regional Issues|November 25, 2016
Cost-Effectiveness Analysis Expands its Reach WorldwideDan Greenberg, Peter J Neumann
Pageof 31